Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The TURis system for transurethral resection of the prostate: a NICE medical technology guidance

Cleves, Andrew, Dimmock, Paul, Hewitt, Neil and Carolan-Rees, Grace 2016. The TURis system for transurethral resection of the prostate: a NICE medical technology guidance. Applied Health Economics and Health Policy 14 (3) , pp. 267-279. 10.1007/s40258-015-0221-2

[thumbnail of art_10.1007_s40258-015-0221-2.pdf]
PDF - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (566kB) | Preview


The transurethral resection in saline (TURis) system was notified by the company Olympus Medical to the National Institute of Health and Care Excellence’s (NICE’s) Medical Technologies Evaluation Programme. Following selection for medical technologies guidance, the company developed a submission of clinical and economic evidence for evaluation. TURis is a bipolar surgical system for treating men with lower urinary tract symptoms due to benign prostatic enlargement. The comparator is any monopolar transurethral resection of the prostate (mTURP) system. Cedar, a collaboration between Cardiff and Vale University Health Board, Cardiff University and Swansea University in the UK, acted as an External Assessment Centre (EAC) for NICE to independently critique the company’s submission of evidence. Eight randomised trials provided evidence for TURis, demonstrating efficacy equivalent to that of mTURP for improvement of symptoms. The company presented meta-analyses of key outcome measures, and the EAC made methodological modifications in response to the heterogeneity of the trial data. The EAC analysis found that TURis substantially reduced the relative risks of transurethral resection syndrome (relative risk 0.18 [95 % confidence interval 0.05–0.62]) and blood transfusion (relative risk 0.35 [95 % confidence interval 0.19–0.65]). The company provided a de novo economic model comparing TURis with mTURP. The EAC critiqued the model methodology and made modifications. This found TURis to be cost saving at £70.55 per case for existing Olympus customers and cost incurring at £19.80 per case for non-Olympus customers. When an additional scenario based on the only available data on readmission (due to any cause) from a single trial was modelled, the estimated cost saving per case was £375.02 for existing users of Olympus electrosurgery equipment and £284.66 per case when new Olympus equipment would need to be purchased. Meta-analysis of eight randomised trials showed that TURis is associated with a statistically significantly reduced risk of transurethral resection syndrome and a reduced need for blood transfusion—two factors that may drive cost saving for the National Health Service. The clinical data are equivocal as to whether TURis shortens the hospital stay. Limited data from a single study suggest that TURis may reduce the rate of readmission after surgery. The NICE guidance supports adoption of the TURis technology for performing transurethral resection of the prostate in men with lower urinary tract symptoms due to benign prostatic enlargement

Item Type: Article
Date Type: Publication
Status: Published
Schools: Engineering
Subjects: R Medicine > R Medicine (General)
T Technology > TA Engineering (General). Civil engineering (General)
Additional Information: First online: 27 January 2016 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
Publisher: Springer
ISSN: 1175-5652
Date of First Compliant Deposit: 30 March 2016
Date of Acceptance: 3 December 2015
Last Modified: 17 Jun 2017 11:18

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics